Rabbit Anti-Human VEGFR-1/Flt-1
Slide this table
|BSA (50x), 0.02% sodium azide
|Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
|Stability and Storage
|The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
|Produced from sera of rabbits immunised with highly pure recombinant human soluble extracellular domain of Flt-1/VEGFR-1 (110 kDa) as the immunizing antigen. Anti-human VEGFR-1/Flt-1 was purified by antigen-affinity chromatography with immobilised recombinant soluble VEGFR-1/VEGFR-1 or by protein A chromatography.
|Recombinant human soluble Flt-1(D1-5)
|vascular endothelial growth factor receptor-1; FLT1; VEGF receptor 1
|Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.
All prices plus VAT + possible delivery charges